Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
© Alves et al; licensee BioMed Central Ltd. 2014
Published: 17 September 2014
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by chronic inflammation that potentially leads to organ damage. Severe manifestations make the management of SLE difficult and challenging. Nonsteroidal antiinflammatory drugs (NSAIDs), antimalarial drugs, glucocorticoids, immunosuppressive and citotoxic agents are the mainstays of treatment. Unfortunately, these agents are related to a vast toxicity. For an amount of patients, these approaches arent enough to achieve disease activity control, especially in those with cytopenia, nephritis and neuropsychiatric lupus. For these cases, Rituximab (RTX) – a chimeric mouse/human monoclonal antibody specific for human CD20 B-cell – has been widely prescribed. It is known that B-cells have a central role in SLE pathogenesis, being precursors of plasma cells production autoantibodies, precipitating inflammation by producing cytokines, activation T-cells by presentation of self-antigens, and regulating T-cells activity via co-stimulatory molecules. Although the clinical trials of RTX in SLE had controversial results, RTX seems to be a valuable option as an off-label drug for refractory patients.
To report the experience of a tertiary pediatric rheumatology center with RTX for patients with refractory SLE.
We performed a retrospective chart review of patients with SLE that received RTX in some moment of their disease from September 2009 to February 2013 due to refractory to traditional therapies. A satisfactory response was defined as reaching SLEDAI reduction in at least 50%, urina protein:creatinine ratio (UPCR) <50 mg/mmol (equivalent to proteinuria <0.5g/24h), and corticoid tapering to at least 50% of inicial dose.
Seven patients were in use of the medication in the revised period. All of then were female. Six patients had the diagnosis of lupus nephritis, and 1 had refractory plaquetopenia to standart drugs. Two patients had an inadequate response to RTX. One of them persisted with refractory plaquetopenia and the other died due to complications related to SLE. Out of the 6 patients with lupus nephritis, 4 (66%) achieved SLEDAI reduction of at least 50% after 4-6 months of RTX, as well showed an important reduction of proteinuria (<0.5g/24h) and corticoid tapering. One patient had improvement of her disease, however without achieving the paramethers of satisfactory response to the RTX. For this reason, this patient was considered to have a partial response to the RTX. The results are according to those found in similar studies.
It is suggested that RTX continues to be used as a therapeutic option for patients with refractory SLE or with contraindication to traditional drugs. Prospected studies are still needed to evaluate efficacy and safety of RTX in pediatric patients.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.